Emcure Pharma Arm Ties Up With Italy’s WiQo To Sell Skin Tightening Product In India; Shares Rise
Emcure Pharmaceuticals Ltd. shares gained on Tuesday after its subsidiary signed a partnership agreement with the Italian derma-cosmetic company WiQo to import and sell ‘PRX-PLUS', used for skin tightening.
The Indian drugmaker announced that its wholly-owned arm, Emcutix Biopharmaceuticals Ltd has entered into an exclusive in-licensing pact with WiQo to "revolutionize derma-cosmetic treatments" in India.
WiQo is an innovative Italian derma-cosmetic and medical device company that specialises in scientifically validated products.
The partnership has granted Emcutix rights to import, promote, distribute as well as sell WiQo' leading product ‘PRX-PLUS' in India, which is a topical painless booster used for skin tightening.
More than 40,000 dermatologists and aesthetic doctors globally use WiQo's patented formulas. In this case, PRX-PLUS is an innovative combination, which provides a formula that instantly tightens the skin, without using any injections, thereby offering a non-invasive, pain-free alternative to traditional aesthetic treatments.
The product is known to be safe for all skin types and prototypes, and can be used in all seasons, the company noted in a press release.
“Our collaboration with WiQo marks a significant step toward fulfilling this commitment, introducing PRX-PLUS, a unique and advanced skincare solution. With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India,” stated CEO of Emcutix Biopharmaceuticals, Sathya Narayanan on Tuesday.
Following the announcement, shares of Emcure Pharmaceuticals rose nearly 2% on the BSE, clocking an intraday high of Rs 1,093.45. The stock pared much of the gains to settle 0.58% higher at Rs 1,079 apiece, compared to a 1.8% decline in the benchmark Sensex.
The dermatology market in India has been witnessing consistent and significant growth over the last few years due to growing awareness about skincare.
As per data provided by Indian Pharmaceutical Market, the market size of the dermatology segment is set to stand approximately at $1.8 billion, showcasing a potential growth rate of 11-12% in the near future.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
